Association of serum interleukin-6 with asthma control and subsequent exacerbations: a retrospective cohort study assessing incremental predictive value

Background Circulating interleukin-6 (IL-6) has been associated with adverse asthma outcomes, but its incremental value beyond routine clinical assessment remains uncertain. We evaluated the associations of serum IL-6 with asthma control and 12-month exacerbations and assessed its incremental value beyond the Asthma Control Test (ACT) and clinical variables. Methods This single-centre retrospective cohort included 984 adults with asthma. IL-6 was analysed as a continuous exposure using Pearson correlation, non-parametric receiver operating characteristic analysis and prespecified hierarchical multivariable logistic regression. Models were sequentially adjusted for basic clinical factors, ACT, forced expiratory volume in 1 s (FEV₁) % predicted and fractional exhaled nitric oxide (FeNO). Sensitivity analyses additionally included blood eosinophils and baseline leukotriene receptor antagonist use. Internal optimism in model discrimination was estimated using 1,000 bootstrap resamples. Results Overall, 347 participants (35.3%) experienced an exacerbation within 12 months. IL-6 correlated negatively with ACT (r = − 0.742), FEV₁ % predicted (r = − 0.588) and FEV₁/forced vital capacity (r = − 0.376), and positively with exacerbation (r = 0.413; all P < 0.001). The area under the curve (AUC) for IL-6 alone was 0.752 (95% confidence interval [CI], 0.721–0.783). Each 1-standard-deviation increase in IL-6 was associated with higher odds of exacerbation after basic adjustment (odds ratio [OR], 2.337; 95% CI, 1.982–2.771; P < 0.001). The association was attenuated after adding ACT (OR, 1.247; 95% CI, 1.001–1.553; P = 0.049) and was not statistically significant after further adjustment for FEV₁ % predicted and FeNO (OR, 1.233; 95% CI, 0.988–1.539; P = 0.063). Adding IL-6 to the ACT-based clinical model increased the AUC from 0.817 to 0.819 (DeLong P = 0.333); the bootstrap-corrected AUC was 0.812. The exploratory IL-6 cut-off was 6.015 pg/mL (sensitivity, 81.0%; specificity, 59.7%). Conclusions Serum IL-6 was associated with poorer asthma control and higher odds of exacerbation, but showed no clear incremental discrimination beyond ACT and clinical variables. Its role as a clinical predictor requires external validation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11198043/v1
Primary Topic
Asthma and respiratory diseases
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Association of serum interleukin-6 with asthma control and subsequent exacerbations: a retrospective cohort study assessing incremental predictive value

Qiming Si, 周丹丹, Yingpei Wei, Jingjiao Liu et al.
2 links
Research Square
Asthma and respiratory diseases
preprint

Association of serum interleukin-6 with asthma control and subsequent exacerbations: a retrospective cohort study assessing incremental predictive value

Qiming Si, 周丹丹, Yingpei Wei, Jingjiao Liu, Da Huang, jianying liu
preprint en

Abstract

Background Circulating interleukin-6 (IL-6) has been associated with adverse asthma outcomes, but its incremental value beyond routine clinical assessment remains uncertain. We evaluated the associations of serum IL-6 with asthma control and 12-month exacerbations and assessed its incremental value beyond the Asthma Control Test (ACT) and clinical variables. Methods This single-centre retrospective cohort included 984 adults with asthma. IL-6 was analysed as a continuous exposure using Pearson correlation, non-parametric receiver operating characteristic analysis and prespecified hierarchical multivariable logistic regression. Models were sequentially adjusted for basic clinical factors, ACT, forced expiratory volume in 1 s (FEV₁) % predicted and fractional exhaled nitric oxide (FeNO). Sensitivity analyses additionally included blood eosinophils and baseline leukotriene receptor antagonist use. Internal optimism in model discrimination was estimated using 1,000 bootstrap resamples. Results Overall, 347 participants (35.3%) experienced an exacerbation within 12 months. IL-6 correlated negatively with ACT (r = − 0.742), FEV₁ % predicted (r = − 0.588) and FEV₁/forced vital capacity (r = − 0.376), and positively with exacerbation (r = 0.413; all P < 0.001). The area under the curve (AUC) for IL-6 alone was 0.752 (95% confidence interval [CI], 0.721–0.783). Each 1-standard-deviation increase in IL-6 was associated with higher odds of exacerbation after basic adjustment (odds ratio [OR], 2.337; 95% CI, 1.982–2.771; P < 0.001). The association was attenuated after adding ACT (OR, 1.247; 95% CI, 1.001–1.553; P = 0.049) and was not statistically significant after further adjustment for FEV₁ % predicted and FeNO (OR, 1.233; 95% CI, 0.988–1.539; P = 0.063). Adding IL-6 to the ACT-based clinical model increased the AUC from 0.817 to 0.819 (DeLong P = 0.333); the bootstrap-corrected AUC was 0.812. The exploratory IL-6 cut-off was 6.015 pg/mL (sensitivity, 81.0%; specificity, 59.7%). Conclusions Serum IL-6 was associated with poorer asthma control and higher odds of exacerbation, but showed no clear incremental discrimination beyond ACT and clinical variables. Its role as a clinical predictor requires external validation.

Research Square
Hebei Yanda Ludaopei Hospital (CN)
Good health and well-being
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon